Zavain Dar

CIK: 0001852075

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)11 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RXRX

RECURSION PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

RXRX
RECURSION PHARMACEUTICALS, INC.
Oct 1, 2026
Award(A)
Direct
4.6K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jul 1, 2026
Award(A)
Direct
5.1K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 17, 2026
Award(A)
Direct
88.4K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Apr 1, 2026
Award(A)
Direct
4.9K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jan 2, 2026
Award(A)
Direct
3.6K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Oct 1, 2025
Award(A)
Direct
2.9K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jul 1, 2025
Award(A)
Direct
2.9K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Direct
22K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Apr 1, 2025
Award(A)
Direct
2.7K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jan 2, 2025
Award(A)
Direct
1.9K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Oct 1, 2024
Award(A)
Direct
2.2K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	4,607	-	$0	Direct
Jul 1, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	5,109	-	$0	Direct
Jun 17, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	88,424	-	$0	Direct
Apr 1, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	4,902	-	$0	Direct
Jan 2, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	3,571	-	$0	Direct
Oct 1, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	2,941	-	-	Direct
Jul 1, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	2,924	-	-	Direct
Jun 18, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	22,016	-	-	Direct
Apr 1, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	2,745	-	-	Direct
Jan 2, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	1,907	-	$0	Direct
Oct 1, 2024	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	2,229	-	$0	Direct

1-11 of 11 transactions

About Dar Zavain

Dar Zavain (SEC CIK 0001852075) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX).

Signal8 holds 11 ownership filings by Dar Zavain, all Form 4s, filed between Oct 4, 2024 and Oct 2, 2026. Those filings report 11 transactions, from Oct 1, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dar Zavain's filings is in SALT LAKE CITY, UT.

Recent filings by Dar Zavain

Oct 1, 2026: Grant or award of RXRX shares (Form 4, code A).
Jul 1, 2026: Grant or award of RXRX shares (Form 4, code A).
Jun 17, 2026: Grant or award of RXRX shares (Form 4, code A).
Apr 1, 2026: Grant or award of RXRX shares (Form 4, code A).
Jan 2, 2026: Grant or award of RXRX shares (Form 4, code A).

Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)

Borgeson Blake, Director
HERSHBERG ROBERT, Director
Li Dean Y, Director
Taylor Ben R, Chief Financial Officer
Khan Najat, CEO and President
Hallett David, Chief Scientific Officer

How to read Form 4 transaction codes